The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases
as neglected tropical diseases. These diseases are caused by parasitic trypanosomatids …

Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis
cause substantial death and morbidity, particularly in low- and middle-income countries. …

The clinical efficacy and safety of a drug is determined by its activity profile across many
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …

There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and
novel modes of action, to widen the scope of treatment and to overcome emerging drug …

… brucei NMT open reading frame was amplified from genomic DNA using suitable primers
and cloned into the plasmid vector pM2cN. The resulting construct encodes the target protein …

Chemical strategies to using small molecules to stimulate hypoxia inducible factors (HIFs)
activity and trigger a hypoxic response under normoxic conditions, such as iron chelators and …

… Please read our Terms of Service before submitting an eLetter. … Register for free to
read this article … Login or register for free to read this article. …

… Summerfield SG, Read K, Begley DJ, Central nervous system drug disposition: the …
People also read lists articles that other readers of this article have read. … People also read …

The von Hippel–Lindau tumor suppressor protein is the substrate binding subunit of the
VHL E3 ubiquitin ligase, which targets hydroxylated α subunit of hypoxia inducible factors (HIFs) …

The success of nifurtimox-eflornithine combination therapy (NECT) for the treatment of
human African trypanosomiasis (HAT) has renewed interest in the potential of nitro drugs as …